Genzyme Sets Sights On 13 Drug Approvals By 2012; Only 2 Are NMEs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Only two new molecular entities are included in Genzyme's plan for 13 drug approvals between now and 2012, CEO Henri Termeer said during the company's annual analyst and investor day May 7
You may also be interested in...
Genzyme/Isis Expand Mipomersen Clinical Trial Program
Findings from additional mipomersen clinical trials announced by Genzyme and Isis Jan. 12 will aid in the design of a subsequent outcomes trial FDA has requested for the cholesterol-lowering drug candidate
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.